This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hock, H. Articles by Blankenstein, T. Search for Related Content PubMed PubMed Citation Articles by Hock, H. Articles by Blankenstein, T.

Vaccinations with Tumor Cells Genetically Engineered to Produce Different Cytokines: Effectivity not Superior to a Classical Adjuvant¹

Institute of Immunology, Free University of Berlin, Hindenburgdamm 27, 1000 Berlin 45, Germany

The potential of tumor cells (J558L) engineered to produce one of 5 different cytokines (interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or -interferon) to give rise to systemic immunity protective against a contralateral challenge with the parental cells was analyzed. The rejection of all cytokine-producing cells appeared to induce some systemic response capable of mediating the rejection of low numbers of subsequently contralaterally injected cells, but the effect was much less obvious with higher cell numbers. The injection of any possible combination of two of the cytokine producers did not reveal any synergistic effects. The cytokine gene-transfected tumor cells were not superior to the parental cells admixed with the adjuvant Corynebacterium parvum with respect to their potential as immunogens to induce immunity.

¹ Supported by the Deutsche Forschungsgemeinschaft.

² To whom requests for reprints should be addressed.

Received 11/ 9/92. Accepted 1/ 4/93.

This article has been cited by other articles:

				S. Olver, P. Groves, K. Buttigieg, E. S. Morris, M. L. Janas, A. Kelso, and N. Kienzle Tumor-Derived Interleukin-4 Reduces Tumor Clearance and Deviates the Cytokine and Granzyme Profile of Tumor-Induced CD8+ T Cells Cancer Res., January 1, 2006; 66(1): 571 - 580. [Abstract] [Full Text] [PDF]

				H.-J. Kim, T. Kammertoens, M. Janke, O. Schmetzer, Z. Qin, C. Berek, and T. Blankenstein Establishment of Early Lymphoid Organ Infrastructure in Transplanted Tumors Mediated by Local Production of Lymphotoxin {alpha} and in the Combined Absence of Functional B and T Cells J. Immunol., April 1, 2004; 172(7): 4037 - 4047. [Abstract] [Full Text] [PDF]

				M. Y. Mapara and M. Sykes Tolerance and Cancer: Mechanisms of Tumor Evasion and Strategies for Breaking Tolerance J. Clin. Oncol., March 15, 2004; 22(6): 1136 - 1151. [Abstract] [Full Text] [PDF]

				E. Linardakis, A. Bateman, V. Phan, A. Ahmed, M. Gough, K. Olivier, R. Kennedy, F. Errington, K. J. Harrington, A. Melcher, et al. Enhancing the Efficacy of a Weak Allogeneic Melanoma Vaccine by Viral Fusogenic Membrane Glycoprotein-mediated Tumor Cell-Tumor Cell Fusion Cancer Res., October 1, 2002; 62(19): 5495 - 5504. [Abstract] [Full Text] [PDF]

				Z. Qin, C. Harders, X. Cao, C. Huber, T. Blankenstein, and B. Seliger Increased Tumorigenicity, but Unchanged Immunogenicity, of Transporter for Antigen Presentation 1-deficient Tumors Cancer Res., May 1, 2002; 62(10): 2856 - 2860. [Abstract] [Full Text] [PDF]

				F. Benchetrit, A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautes-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism Blood, March 15, 2002; 99(6): 2114 - 2121. [Abstract] [Full Text] [PDF]

				H.-M. Hu, H. Winter, W. J. Urba, and B. A. Fox Divergent Roles for CD4+ T Cells in the Priming and Effector/Memory Phases of Adoptive Immunotherapy J. Immunol., October 15, 2000; 165(8): 4246 - 4253. [Abstract] [Full Text] [PDF]

				G. Willimsky and T. Blankenstein Interleukin-7/B7.1-encoding Adenoviruses Induce Rejection of Transplanted but not Nontransplanted Tumors Cancer Res., February 1, 2000; 60(3): 685 - 692. [Abstract] [Full Text]

				S. Todryk, A. A. Melcher, N. Hardwick, E. Linardakis, A. Bateman, M. P. Colombo, A. Stoppacciaro, and R. G. Vile Heat Shock Protein 70 Induced During Tumor Cell Killing Induces Th1 Cytokines and Targets Immature Dendritic Cell Precursors to Enhance Antigen Uptake J. Immunol., August 1, 1999; 163(3): 1398 - 1408. [Abstract] [Full Text] [PDF]

				T. Schuler, Z. Qin, S. Ibe, N. Noben-Trauth, and T. Blankenstein T Helper Cell Type 1-associated and Cytotoxic T Lymphocyte-mediated Tumor Immunity Is Impaired in Interleukin 4-deficient Mice J. Exp. Med., March 1, 1999; 189(5): 803 - 810. [Abstract] [Full Text] [PDF]